Navigation Links
Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
Date:5/27/2008

LOS ANGELES, May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today reported that CorCell Companies Inc., Philadelphia, Pa., which it acquired in October 2006, had its first operationally profitable quarter ever for the three months ending March 31, 2008.

CorCell, at the time of the purchase, was the fourth largest umbilical cord blood bank in the U.S. Established in 1995, CorCell collects umbilical cord blood stem cells from hospitals in all 50 states and internationally. CorCell is especially known for its strategic partnerships with health insurers throughout the country.

"When we acquired CorCell, it was losing $150,000 per month. With lots of re-engineering and hard work, the team has put the company in position to be highly successful. By streamlining CorCell's operations, we have turned it into a profitable entity," said Matthew Schissler, CEO, Cord Blood America. "We look for a continuation of this positive trend throughout 2008."

On May 20, 2008, the Company filed its Form 10-QSB with the United States Securities and Exchange Commission. In this document, it is noted that the Company posted an operational loss of $400,000. Mr. Schissler commented, "We have six subsidiaries under the parent Company. The operational loss came from losses of other business units, public Company expenses, and depreciation and amortization. Our operational loss decreased over 20% year over year. We're very excited for getting our largest business unit with the highest gross profits to achieve operational profitability first."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Iowa Resident Dies After Using Contaminated Blood Thinner
2. Global Blood Resources On-Line Calculator Reveals Wasted Blood Costs by Blood Salvage Machines During Heart Surgery to be in the Billions
3. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
4. Cord Blood America in Top 20 in Los Angeles Area Biotech-Biomed Companies
5. Cord Blood America Reports $5.8 Million In Revenues In 2007, Up 74 Percent
6. Stem Cells From Menstrual Blood Show Therapeutic Potential
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
9. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
10. Device That Clears Debris From Artery Aids Blood Flow in PCI
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Italy (PRWEB) , ... April 30, 2016 , ... The ... extraordinary textile design, the bioLogic team explored how bacterial properties can be applied to ... of using Natto bacteria, which move in response to humidity change. The team harvested ...
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
(Date:4/28/2016)... April 28, 2016 Q ... the Company,s CEO  was featured in an article ... When VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... magazine is an essential business journal for ... emerging biotechs to Big Pharmas. Their content is ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
Breaking Biology News(10 mins):